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Madhura Shirish Shukla 
ROLE OF PERK IN ANCHORAGE- INDEPENDENT GROWTH OF COLORECTAL 
CARCINOMA AND CELL MIGRATION IN-VITRO 
The unfolded protein response (UPR) is important for cell adaptation to 
accumulation of unfolded proteins in the endoplasmic reticulum (ER). A central UPR 
sensor of ER stress is PKR- like ER Kinase (PERK), which phosphorylates eIF2 to 
reduce global translation and help mitigate ER stress. While this is a survival mechanism 
that serves to save the cell from catastrophic events during ER stress, PERK can also be 
activated in cancer cells due to genetic changes and exposure to stresses inherent in the 
tumor micro-environment. Published reports have indicated that PERK is activated in 
cancer cells in response to hypoxia, nutrient deprivation, matrix detachment, and 
increased protein load by oncogene activation to facilitate cell survival. The UPR features 
PERK and another ER stress sensory protein, IRE1α, which also regulates the dynamic 
assembly of the actin cytoskeleton; loss of either PERK or IRE1α functions decrease cell 
migration activity. We hypothesized that PERK is required for anchorage-independent 
survival of the cancer cell line HCT116 and that PERK is essential for cell migration. 
Consistent with these premises, inhibition of PERK using pharmacological inhibitors 
GSK2656157 and LY-4 in suspended cells showed reduced growth. Furthermore, PERK-
deficient cells showed reduced migration in transwell migration assays as compared to 
their wild type counterpart. These results suggest that PERK facilitates anchorage-
independent growth of cancer cells and cell migration. 
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Disruption of ER homeostasis leads to activation of the unfolded protein response 
The endoplasmic reticulum (ER) is a system of membranous tubules that is 
central for synthesis, folding, assembly, and transport of proteins designated for the 
secretory pathway.  Furthermore, the ER is central for calcium storage and release and for 
lipid synthesis. Chaperones localized in the ER participate in protein folding and 
assembly and there is further post-translational modification of newly synthesized 
proteins in this organelle. Misfolded proteins are detrimental to the cell and therefore 
need to be appropriately eliminated. When there is accumulation of unfolded proteins in 
the ER, it disrupts protein homeostasis and leads to ER stress. Terminally misfolded 
proteins are subjected to degradation via ER associated degradation (ERAD) pathway.  
 
In addition to conditions directly linked to misfolded proteins, ER stress is caused 
by genomic instability, hypoxia, changes in temperature, and reactive oxygen species 
(ROS) (1-5). Pharmacological agents, such as thapsigargin (Tp), can induce ER stress. 
Thapsigargin blocks the calcium pump Sarco/Endoplasmic Reticulum Calcium ATPase 
(SERCA) in the ER, resulting in rapid release of Ca2+ from the ER. Calcium depletion 
from the ER leads to loss of activity of calcium dependent chaperones in the ER that 
triggers accumulation of unfolded proteins and ultimately ER stress (6,7). Another 
pharmacological agent that induces ER stress is tunicamycin, which thwarts N-





Accumulation of misfolded proteins activate one of the three ER stress sensors: 
PKR-like ER Kinase (PERK), Activating Transcription Factor 6 (ATF6), and Inositol 
Requiring Enzyme 1 (IRE1).  Collectively, the signaling response mounted by these ER 
stress sensors is referred to as the Unfolded Protein Response (UPR). It is suggested that 
under non-stressed conditions, these ER transmembrane proteins are bound by the 
chaperone BiP (GRP78, HSPA5) and thus remain inactive. But accumulation of 
misfolded proteins competes for BiP binding to these sensory proteins, leading to release 
of the chaperon. Upon the release of BiP, PERK and IRE1α dimerize, triggering 
autophosphorylation that contributes to their activation (1,8-10).  Additional models of 
activation suggest that IRE1α and PERK can be directly bound to unfolded protein that 
accumulate during ER stress, leading to their autophosphorylation and enhanced 
signaling (11,12).   
 
IRE1α possesses protein kinase and riboendonuclease activities. Upon activation, IRE1α 
riboendonuclease directs the cleavage and removal of a segment of X-box binding protein 
1 (XBP1) mRNA, and the remaining portion of the transcript is ligated by a tRNA ligase 
RTCB (13). The cytosolic splicing of the XBP1 transcript leads to translation of an active 
basic leucine zipper (bZIP) transcription factor that enters the nucleus and binds to ER 
stress response elements (ERSE) in the target promoters of UPR genes. ATF6 is another 
bZIP transcription factor that upon ER stress is transported to the Golgi apparatus, where 
ATF6 is cleaved via S1 and S2 proteases, leading to release of an amino terminal portion 
of ATF6, designated ATF6(N), that is released from the Golgi into the cytosol. ATF6(N) 





Figure 1: Depiction of activation and cascade of various stress sensors of UPR and 
ISR 
Different intrinsic and extrinsic cell stresses cause accumulation of misfolded 
proteins in the endoplasmic reticulum leading to stress of this organelle. Three ER 
transmembrane proteins, PERK, ATF6, and IRE1α, monitor perturbations in the ER 
lumen and membrane. Sensing of the ER stress is suggested to involve release of 
inhibitory interactions with an ER chaperone, BiP. Activation of IRE1α and ATF6 leads 
to induction of bZIP transcription factors XBP1 and ATF6(N), respectively. These ER 
sensors upregulate the transcription of UPR-target genes to mitigate stress damage. Four 
eIF2 kinases, GCN2, PERK, HRI, PKR, are activated by different cellular stresses, 




Phosphorylation of this translation initiation factor reduces global protein synthesis 
accompanied by preferential translation of gene transcripts required to adapt to the stress.  
 
The third ER stress sensor PERK is a serine/threonine kinase that phosphorylates 
the α subunit of eukaryotic initiation factor 2 (eIF2α) at serine-51 to regulate translation 
control in the UPR (15,16).  PERK has also been reported to also phosphorylate nuclear 
factor erythroid 2–related factor 2 (NRF2), Diacyl glycerol (DAG), and Forehead box O 
protein (FOXO) (17-19), although these signaling processes have not been extensively 
studied. 
 
Global translation repression and preferential translation of stress adaptive genes 
reinstate ER homeostasis 
One of the major substrates of PERK is eIF2, which binds to GTP and delivers 
initiator methionyl tRNA (Met-tRNAi
Met) to the 40S ribosome for initiation of mRNA 
translation. During the translation initiation process, the GTP associated with eIF2 is 
hydrolysed to GDP.  The GDP on eIF2 must then be exchanged for GTP by the guanine 
nucleotide exchange factor eIF2B, for the further translation initiation. During ER stress, 
PERK phosphorylation of eIF2α thwarts the eIF2B-directed exchange, sharply lowering 
the levels of eIF2-GTP that results in reduced delivery of initiator tRNA to ribosomes.  
The resulting reduction in global protein synthesis lowers energy and nutrient 
expenditure, facilitating cell adaptation to the underlying stress. Additional eIF2 kinases 
in mammalian cells include General Control Nonderepressible 2 (GCN2), Heme 




nutrient deprivation (9,20) and in response to UV irradiation (21). HRI is activated in 
reticulocyte cells in response to heme or iron deprivation (22) and mitochondrial stress 
(23,24), whereas PKR is activated by viral infections (25). In addition to accumulating 
misfolded proteins, disruption of calcium homeostasis and lipid synthesis can also cause 
ER stress that enhances PERK eIF2 kinase activity (1,10). Phosphorylation of eIF2α 
represses global translation initiation in the cell coincident with enhanced preferential 
translation of certain genes involved in transcription, protein turnover, and cell cycle.  
Because the four different eIF2 kinases regulate translation in response to diverse stress, 
this pathway is collectively referred to as the Integrated Stress Response (26). 
 
In mammals, eIF2α-P is well documented to enhance translation of Activating 
Transcription Factor 4 (ATF4), a bZIP transcription factor. Translation of ATF4 involves 
upstream open reading frames (uORFs) present in the 5’-leader of its gene transcript; 
preferential translation of ATF4 upon eIF2α phosphorylation by a mechanism of delayed 
translation reinitiation (27). Increased levels of ATF4 protein then direct target promoters 
of ISR genes, including those encoding C/EBP- homologous protein (CHOP), Growth 
arrest and DNA damage inducible 34 (GADD34) protein, and Inhibitor of Bruton 
Tyrosine Kinase (IBTKα), each of which are also subject to preferential translation (28-
30). CHOP is a bZIP transcription factor responsible for apoptotic cell fate and its mRNA 
is also preferentially translated by a mechanism involving an uORF (31). GADD34 is a 
scaffolding protein, which is induced by both transcriptional and translational 
mechanisms in the ISR (32-34). GADD34 forms a complex with type 1 protein 




PERK integrates the UPR and ISR in order to alleviate disruptions in protein homeostasis 
and restore the health of the ER. 
 
Role of PERK in cancer 
Cancer cells face a multitude of intrinsic and extrinsic stresses, many of which 
directly or indirectly disrupt the functions of the ER. A major intrinsic perturbation in 
cancers is genome instability. An example is in chronic myeloid leukemia that features a 
chromosome translocation that produces BCR-ABL1, an active oncoprotein. Production 
of this oncoprotein disrupts ER homeostasis and ER-mediated calcium-dependent 
apoptotic responses (1,38). Furthermore, amplification of Myc oncogene facilitates cell 
growth and proliferation involving increased ribosome production and increased mRNA 
translation. Enhanced protein synthesis can overwhelm the protein folding machinery, 
leading to ER stress and PERK activation. The ensuing stress response helps cancer cells 
adapt to Myc induction and other external stresses encountered by the cell.  Activation of 
PERK has been reported in a number of other cancers, including lymphomas and those 
affecting the prostate (39-41).  
 
Extrinsic stresses involving hypoxia, glucose and nutrient deprivation, and ROS 
accumulation occur in tumor microenvironment, triggering ER stress (1,39). Hypoxia 
leads to PERK activation, which helps tumor cells to adapt to the oxygen depletion;  loss 
of PERK can lead to apoptosis of cancer cells in hypoxic environments and reduction of 
tumor size (42,43). It was also reported that in breast adenocarcinoma cells, PERK and 




reduce migration in-vitro (44). PERK is important for alleviating ROS production, which 
can elicit DNA damage (45). Apart from intrinsic and extrinsic factors inherent in cancer 
cells proliferation and progression, PERK also plays a role in cancer cell survival against 
chemotherapeutic agents by upregulating multidrug resistance related protein (MPR1) via 
a pathway involving PERK induction of NRF2, as reported by Salaroglio I. C. et al (46). 
 
Resistance of anoikis in cancer 
Anoikis is a form of apoptotic cell death that is triggered upon detachment of cells 
from the extracellular matrix. Some normal migratory cells, such as leukocytes, are 
protected from anoikis due to their amoeboid migration (47). ECM detachment and 
migration are primary steps leading to metastasis, and this process requires cancer cells to 
be resistant to anoikis. When cells detach from ECM, the apoptotic pathway is triggered 
due to the absence of pro-survival responses provided with cell-ECM interactions 
(48,49). PERK induces autophagic responses during matrix detachment in breast cancer 
cells and this eIF2 kinase promotes antioxidant responses against ROS to protect the cells 
from anoikis (50). 
 
Cell Migration and UPR 
Cell migration is an important phenomenon in cancer progression. The role of cell 
migration in metastasis process involves three critical steps: 1) detachment of tumor cells 
from the original site of the tumor, 2) survival of the cancer cells during anchorage-
independence, and 3) cancer cell reattachment at a new metastatic site. Cancer cells 




part of epithelial–mesenchymal transition (EMT) and entrance of cancer cells into the 
blood stream. Initiation of migration requires changes in polarity of the cells to form a 
leading edge and polarity is achieved by remodelling of the actin cytoskeleton. After 
survival through the anchorage-independence through the blood stream, the cancer cell 
attaches to the secondary site by reverse process of EMT: mesenchymal- epithelial 
transition (MET) (51,52). Various stresses are experienced by cancer cells during 
migration and metastasis, which can activate the UPR pathway to mitigate stress damage. 
For example, expression of ATF4 is enhanced by HER2 overexpression in breast cancer 
cells and increased levels of ATF4 are suggested to promote cell migration by inhibiting 
E-cadherin expression (53). In some types of cancers, UPR activators PERK and IRE1α 
are shown to drive cell migration in response to hypoxia and ER stress inducing 
conditions via ATF4 and XBP1 (44,54,55). 
 
In a normal epithelial cell, cortical distribution of F-actin maintains cell shape, but 
upon receiving a migratory stimulus, actin stress fibers are formed to project filopodia 
and lamellipodia for cell migration (56,57). Both IRE1α and PERK are suggested to 
contribute to the dynamics of the actin cytoskeleton. IRE1α interaction activates filamin 
A, a key factor in actin polymerization, to cause actin remodelling via Rho GTPase. 
IRE1α deficient cells showed fewer filopodia and lamellipodia protrusions that contribute 
to reduced migration suggesting that IRE1α is required for cell migration (58). PERK  
also associates with filamin A and causes cortical F-actin distribution that affects cell 
migration in a wound closure assay (59).  It is noteworthy that the enzymatic activities of 




sensory proteins can serve as scaffolding proteins for complex signalling networks.  
 
Questions addressed in this thesis 
The aim of this study is to address the role of PERK in cancer progression, 
specifically in in cancer cell migration and anchorage-independent growth. Three 
questions are addressed: Does matrix detachment cause ER stress in colorectal cancer 
cells and attendant induction of the UPR? What role does the UPR play in anchorage-
independent survival and growth of the cancer cells? Finally, what function does PERK 
play in cell migration? Addressing these critical questions is important to provide new 





MATERIALS AND METHODS 
 
Cell culture 
The human colorectal adenocarcinoma cell line, HCT116 (ATCC, CCL-24) was 
cultured in 1X McCoy’s 5A (modified) media containing 0.22 g/L L-Glutamine (Sigma 
Aldrich, M4892) that was supplemented with 10% FBS and 2.2g/L sodium bicarbonate. 
Cells were cultured until 70-80% confluency and fed every 2-3 days. Freezer stocks of 
the HCT116 cells were prepared in 1X McCoy’s 5A+ 20% FBS+ 5% DMSO and stored 
in liquid nitrogen. 2X media for soft agar assays was prepared from powdered McCoy’s 
5A media (Sigma Aldrich, M4892) supplemented with 4.4 g/L sodium bicarbonate and 
20% FBS. 
 
Mouse embryonic fibroblast (MEF) cells (60) were cultured in 1X Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Fisher Scientific, MT10013CV) supplemented with 
10% FBS. The cells were passaged until 70-80% confluency. Fresh media was added to 
the cultures every 2-3 days. Freezer stocks were prepared in 1X DMEM+ 20%FBS+ 10% 
DMSO and stored in liquid nitrogen. PERK-/- MEF cells were isolated from embryos 
from PERK knock-out animals as described in Jiang H.Y. et al (60). 
 
To facilitate cell passage, cells were trypsinized using TrypLE express (Fisher 
Scientific, 12605-010) for 5-7 minutes at 37oC. Cell counting was performed by mixing 
10 µL of cell suspension and 10µL of 0.4% Trypan blue. 10µL of this mixture was 




1450102). The unstained cells in the size range of 8-25 µm were counted as live cells. 
Live cell count was used to seed cells for tumor sphere and migration assays. 
 
Preparation and quantification of protein lysates 
Lysate preparation from adherent cells 
Cells were plated in 6-well plates for overnight growth. The next day, sub-
confluent cells were removed using a sterile cell scraper, collected by centrifugation, and 
washed twice with 5 mL of 1X PBS. Lysates were prepared in 80 µL 1% SDS lysis 
solution supplemented with 1X protease and phosphatase inhibitor cocktail (Thermo 
Fisher; 78444).  Whole cell lysates were incubated at 95oC for 5 minutes and then cells 
were subjected to 15 pulses of sonication using a VWR Branson 450 Sonifier with Probe 
at timer 0.2, duty cycle 20%, output control 4. Lysates were clarified by centrifugation at 
12000 RPM for 15 minutes at room temperature in an Eppendorf 5424 centrifuge. 
Clarified supernatants were transferred to a fresh microfuge tube and used for protein 
quantification using a Bradford Bio-Rad DC protein assay, which involves a colorimetric 
protein determination using Coomassie blue. Absorbance was measured at 750 nm and 
the concentration of each lysate was determined by using bovine serum albumin (BSA) 
standards ranging from 0.2- 1.0 mg/mL (Bio-Rad). 
 
Lysates preparation from non-adherent spheres 
Cultured spheres that were suspended in growth media were collected into a 
sterile 15 mL Falcon conical centrifuge tube and subjected to centrifugation at 200 x g for 




removed, and the collected spheres were washed twice in 1X PBS solution and lysed 
using 80 µL 1% SDS solution supplemented with 1X protease and phosphatase inhibitor 
cocktail (Thermo Fisher; 78444). Lysates were incubated at 95oC for 5 minutes and the 
cell preparation was subject to sonication for 15 pulses using VWR Branson 450 Sonifier 
with Probe at timer 0.2, duty cycle 20%, output control 4. Lysates were clarified by 
centrifugation at 12000 RPM for 15 minutes at room temperature in Eppendorf 5424 
centrifuge. Clarified supernatants were transferred to a fresh tube and used for protein 
quantification. Protein quantification of all lysates was done using the Bio-Rad DC 
protein assay.  
 
SDS-PAGE and western blot analysis 
4X laemmli sample buffer solution was prepared by mixing 900 µL of 4X 
laemmli buffer stock (Bio-Rad; 161-0747) with 100 µL of -mercaptoethanol. 4X 
laemmli sample buffer solution (5µL) and SDS lysis buffer were mixed with 20 µg of 
protein sample in total 20 µL volume. Samples were boiled for 5 minutes and proteins 
were separated by electrophoresis in a 10% TGX stain-free FastCast acrylamide gel (Bio-
Rad; 161-0173) using 1X SDS running buffer for 1.5 h at 90-120 volts. Precision Plus 
Dual color protein standards (Bio-Rad; 1610374) were used with each gel to delineate 
protein molecular weights.  
 
Separated proteins were transferred to nitrocellulose membranes using a Bio-Rad 
TransBlot machine and TransBlot transfer buffer solution at a current of 1.3A, up to 25V 




grade milk (Bio-Rad; 1706404) in 1X TBST for 1 h at room temperature. Primary 
antibodies for target proteins were then added, followed by incubation overnight in a 
solution of 5% blocking grade milk at 4oC with gentle rocking. The membranes were 
then washed three times for 10 minutes each with a 1X TBST buffer solution. HRP-
conjugated secondary antibody complementary to the primary antibody was diluted 
1:5000 in 5% blocking grade milk solution and incubated for 1 h at room temperature 
with mixing. A list of primary and secondary antibodies, their dilutions used in 
experiments, and their description are provided in Table 1. ATF4 and phospho-PERK 
antibodies were made as described by Teske B. F et al and Tenkerian C. et al, 
respectively (61,62). Membranes were washed with 3 times with 1X TBST solution, each 
for 10 minutes, to remove unbound antibody from the membranes and protein bands were 
detected using ECL-enhanced chemiluminescence reagents (Bio-Rad; 1705060). Images 
of chemiluminescent protein bands and colorimetric protein ladders were captured using 
‘optimal auto exposure’ in the Bio-Rad ChemiDoc imaging system. Chemiluminescent 
and colorimetric images were superimposed to note the relative positions of protein bands 











Table 1: List of antibodies and their dilutions used in western blot analysis 
List of primary antibodies used for western blot analysis to detect ATF4, beta-actin, 
GADD34, phospho-eIF2, phospho-GCN2, phospho-PERK, total eIF2 and total PERK 
used at their standard dilution. The secondary antibodies against rabbit or mouse were 
used at 1:5000 dilution and were detected using HRP-conjugated ECL reagents.  
 
Protein detected Dilution Type Source 
ATF4 1:5000 Rabbit, primary Ab Original (61) 
Beta-Actin 1:5000 Mouse, primary Ab Sigma-Aldrich, A5441 
GADD34 1:500 Rabbit, primary Ab ProteinTech,10449-1-AP 
Goat Anti-Mouse 1:5000 HRP conjugate IgG  Bio-Rad, 170-6515 
Goat Anti-Rabbit 1:5000 HRP conjugate IgG Bio-Rad, 1721019 
Phospho-eIF2 (Ser 51) 1:500 Rabbit, primary Ab Abcam, Ab32157 
Phospho-GCN2 1:500 Rabbit, primary Ab Abcam, Ab75836 
Phospho-PERK 1:500 Rabbit, primary Ab Original (62) 
Total eIF2 1:3000 Rabbit, primary Ab Cell Signaling Technology, 
D7D3 XPR 
Total PERK 1:500 Rabbit, primary Ab Cell Signaling Technology, 
C33E10 
 
Formation of tumor spheres 
Using poly-HEMA coated plates 
To determine the function of PERK in anchorage- independent growth, we used 
culture plates coated with poly-HEMA which inhibit the attachment of cells to the culture 
plate, causing cells to remain suspended (63,64). This coating method allowed for easy 
isolation of protein lysate as compared to matrix-based 3D cultures. The poly-HEMA 
stock was prepared using poly-2-hydroxyethyl methacrylate (Aldrich, 192066) in the 
following protocol: 2g of poly-HEMA powder was added to a final volume of 100 mL of 
95% ethyl alcohol in a sterile bottle. The solution was prepared by heating at 65oC and 




dissolved into the solution. Poly-HEMA solution (4 mL) was added per 10 cm dish 
ensuring uniform distribution over the surface of the plate. Plates were kept open 
overnight at room temperature for drying using sterile technique inside of a biosafety 
cabinet. HCT116 cells were then washed with 1X PBS, trypsinized and mixed with 
normal growth media to prepare a single cell suspension. A sample of 105 cells were 
seeded onto each 10 cm cell culture dish coated with poly-HEMA and the plates were 
incubated at 37oC in 5% CO2 incubator for 15 days to allow sphere formation.  
 
Soft agar assay 
Soft agar assays were performed in 12-well plates that were coated with 500 
µL/well of poly-HEMA stock and dried. A 0.7% agar solution was prepared and 
sterilized to be used as matrix and 300 µL of the solution was added onto the poly-
HEMA coated surface to make ‘base agar layer’. Parental HCT116 cells were washed 
with a 1X PBS solution, trypsinized and then mixed with 2X McCoy’s 5A media to make 
a single-cell suspension. The cell suspension was diluted with 2X media such that there 
were 1000 cells per 300 µL of media solution. The 300 µL of the cell/media suspension 
was then mixed with 300 µL of agar stock (at approximately 40oC), thus making the final 
media concentration 1X and 0.35% agar. The agar and cells were gently mixed and added 
on top of the base agar layer. Once the agar solidified, 600 µL 1X normal growth media 
was added on top of the agar. The wells were then seeded with DMSO control, or the 
indicated amounts of LY-4 and GSK2656157, each with three replicates. The cultured 




well were taken with 10X objectives of inverted compound microscope to quantify the 
assay. 
 
Transwell cell migration assay 
Transwell migration was performed using 8 µm PET membrane inserts (Greiner 
bio-one, 662638) coated with collagen I (Corning, 354249). The collagen I solution was 
prepared by mixing 10.7 µL collagen I stock (9.3 mg/mL) with 990 µL 70% molecular 
biology grade ethanol. 50 µL of the collagen solution was added on top of the membrane, 
making the final collagen concentration on the membrane to be approximately 15 µg 
/cm2. The coated membrane inserts were placed in 24-well plates and dried overnight. 
The next day, wild type MEF cells or their PERK-/- counterparts were washed with 1X 
PBS, trypsinized and then mixed with normal growth media. Cells were collected by 
centrifugation at 200 x g for 5 minutes to remove media. The cell pellet was washed with 
1X PBS solution followed by centrifugation. The cells were then suspended in 1X 
DMEM media without FBS and cell density was determined by cell counting. 500 µL of 
1X DMEM supplemented with 10% FBS was added in each well and the inserts were 
placed on top, making sure that the media in the bottom did not flow back inside the 
insert. Then 20,000 cells were added inside the filter with 200 µL of 1X DMEM without 
FBS. While setting up migration assay with PERK inhibitor GSK2656157, the compound 
was added in both, insert and the lower chamber at 2 µM. The cells were allowed to 






Figure 2: Arrangement of transwell migration assay 
The figure depicts the arrangement of transwell migration assay. The transwell 
insert with collagen coated membrane separates the upper and lower chambers while 
allowing the cells to migrate through it. The lower chamber contains growth media with 
attractant (10% FBS) that facilitates cell migration. The insert is removed using forceps. 
 
For fixing cells, 4% paraformaldehyde (PFA) solution was prepared by mixing 4 
g of PFA to 50 mL 1X PBS solution with gentle stirring on heating block at 60oC. Then 
the mixture was cooled down to room temperature and the pH was adjusted at 7.4 with 
1M HCl. The final volume was made to 100mL using 1XPBS. The 4% PFA solution was 
filtered through 0.45 µm filter and used for fixing (or stored at -20oC) membrane of 
transwell migration assay. After each timepoint, the inserts were removed from media 
and placed in 600 µL of 4% PFA in 1X PBS solution for 15 minutes. The membrane 
inserts were washed twice using a 600 µL 1X PBS solution for 10 minutes per wash. The 
fixed membranes were stored in 1X PBS solution at 4oC until stained. The membranes 
were cut out by poking a syringe around the rim and the membrane segment was then 
placed in DAPI mixed with Prolong Gold Antifade reagent (Invitrogen, P36935) on slide. 




Antifade reagent were mixed on slide. The membrane was then placed in the mixture 
such that the bottom of the membrane touches the slide and coverslip was placed on top. 
The bottom of the membrane was observed under 40X objective using a fluorescence 
microscope and 3 random fields of each membrane was captured to quantify migrated 
cells. 
 
Assay quantification and statistical analysis 
For soft agar assay, the number of spheres per field were counted manually and 
then averaged. The area of the sphere was measured using software ImageJ (65). 
Freehand circles were drawn over the border of each sphere using the ‘freehand drawing’ 
tool and then analyze> measure command gave the area of sphere marked by the circle 
(as represented in Figure 3). The average area was calculated from two biological 
replicates from a total of 90-95 spheres per treatment. 
 
For transwell migration assays, the number of migrated cells per field were 
counted and averaged. The assay was seeded in duplicate per treatment per timepoint. 
Three random fields were captured per insert and the cell count per field was averaged 
from 6 fields at each timepoint. The P value was calculated using two-tailed student’s T-






Figure 3: Measurement of sphere area from soft agar assay using ImageJ 
A. Depiction of free-hand drawing of boundary surrounding the sphere to measure 
its area. B. The panel shows selected free hand drawing tool in ImageJ and the lower 
















Activation of PERK at late stages of sphere formation during anchorage-
independent growth of colorectal carcinoma cells in vitro 
PERK is reported to participate in anoikis resistance upon matrix detachment 
(50), suggesting that the eIF2 kinase is activated during anchorage-independent growth. 
To test this possibility, HCT116 cells were grown in suspension for up to 15 days and the 
formation of spheres was monitored by microscopy. In addition, protein lysates were 
prepared every third day to test for activation of the PERK and its downstream effectors. 
Poly-HEMA coated plates were used to facilitate anchorage-independent growth of 
HCT116 tumorspheres. A protein lysate at day 0 was prepared from a cell suspension 
prior to seeding. Cells (1x105) were seeded in 10 cm cell culture dishes as single cell 
suspension and the growth of tumorspheres was tracked on days 1, 3, 6, 9, 12, 15 by 
capturing images of five random fields. To quantify the growth of spheres over time, the 
sphere area of 15 to 20 spheres was measured for each timepoint and plotted. During 
initial suspension, the cells were clumped together (day 1) and then started forming 
tumorspheres at day 3 (Figures 4A and B). The growth of tumorspheres increased 





Figure 4: Anchorage-independent growth of HCT116 and PERK activation. 
A. Growth of three-dimensional spheres of HCT116 cells for up to 15 days. B. 
Quantification of growth of spheres over 15-day period. The area of the sphere is 
represented as mean ± SEM. Statistical significance was determined by two-tailed 
student’s T-test at P<0.05; n=15 to 20. ***P=0.0007, ****P<0.0001. C. Western blot 




adherent conditions from day 0 to day 15. Thapsigargin treatment (Tp; 1 µM for 6 h) and 
halofuginone treatment (HF; 100 nM for 6 h) on normal adherent cells represent controls 
for PERK and GCN2 activation, respectively. 
 
To evaluate the regulation of the key markers in the ISR we measured their total 
and phosphorylation levels by western blotting (Figure 4C). Controls for the experiments 
included treatment with thapsigargin, which is a robust inducer of ER stress and PERK 
activator, and halofuginone- an inhibitor of prolyl tRNA synthetase that mimics nutrient 
depletion and activates GCN2 (66). During the anchorage-independent growth, PERK 
showed modest phosphorylation during the early time course, with robust activation at 
the later stages, day 12 to day 15 (Figure 4C). Minimal phosphorylation of GCN2 was 
detected during the time course. As expected, thapsigargin induced phosphorylation of 
PERK but not GCN2 and halofuginone potently induced phosphorylation of GCN2. The 
levels of phosphorylation of eIF2α were largely unchanged during the growth period. 
There was a gradual increase in GADD34 throughout the course of sphere formation. The 
constant levels of phosphorylated eIF2 can be attributed to negative regulation by 
increasing levels of GADD34. The measurement of -actin was used as a control for 
normalization to ensure similar levels of total protein were being analyzed. In conclusion, 
PERK activation occurs during the development of tumorspheres. Factors that activate 
PERK during late stage of sphere formation could be hypoxia or certain forms of nutrient 






PERK inhibition by knockout or pharmacological inhibitors 
To address the importance of PERK activation in HCT116 tumorsphere 
formation, we tested two PERK inhibitors in the soft agar assay. GSK2656157 is an 
established PERK inhibitor developed from previous PERK inhibitor compounds to gain 
higher selectivity for the ATP pocket in the kinase domain of PERK (67,68), but does 
have some off target affects against other protein kinases (69). LY-4 is a highly selective 
PERK inhibitor (70,71). To first test the utility of these inhibitors to inhibit PERK 
activity in HCT116 cells, we used thapsigargin to induce ER stress and PERK activation 
in the absence or presence of each compound.  
 
HCT-116 cells were treated with GSK2656157, LY-4, or vehicle (DMSO) as a 
control for 30 minutes, followed by 1 µM thapsigargin for 4 h to induce PERK activation. 
Levels of PERK and eIF2α phosphorylation were measured in the treated cells by 
western blotting. DMSO was used as vehicle control for both PERK inhibitors. 
Thapsigargin treatment was done in combination with DMSO vehicle as a control for 
PERK activation. Halofuginone treatment was also performed as a control for GCN2 
activation (Figure 5). To ensure proper normalization of protein levels, -actin was also 
measured in the western blot analyses. DMSO vehicle treated cells showed increased 
levels of phosphorylated PERK and eIF2, and increased protein levels of their 
downstream targets ATF4 and GADD34 (Figure 5A). Whereas, halofuginone treated 
control cells did not activate PERK. Pre-treatment of HCT116 cells with either LY-4 or 
GSK2656157 substantially ablated the induction of phosphorylation of PERK and 




with thapsigargin (Figure 5A). Taken together, LY-4 and GSK2656157 compounds were 
confirmed to be potent PERK inhibitors in HCT116 cells. 
 
 
Figure 5: PERK inhibition by knockout and pharmacological inhibitors.  
A. HCT116 cells were incubated with 2 µM of LY-4, GSK2656157, or DMSO 
vehicle 30 minutes prior to 4 h treatment with thapsigargin, as indicated. Halofuginone 
that selectively activated eIF2 kinase GCN2 was used as a control. Lysates were 
prepared, separated by SDS-PAGE, and the indicated proteins were measured by western 
blot analyses. Migration positions of pf of marker proteins are indicated to the left of each 
panel. B. Wild-type (WT) MEF cells and their PERK-KO counterparts were treated with 
thapsigargin as indicated and the indicated proteins were measured by western blot 
analyses. PERK inhibitors LY-4 and GSK2656157 were added 30 minutes prior to 
thapsigargin treatment. Tp= 1 µM Thapsigargin for 4 h and HF= 100 nM Halofuginone 




We extended our analysis of the inhibitors using MEF cells. PERK-deleted MEF 
cells were reported by Jiang H.Y. et al (60) and these cells provided useful controls for 
our analysis of the PERK inhibitors. Wild-type and PERK-/- MEF cells were cultured to 
sub-confluency and treated with 1µM thapsigargin for 4 h. In wild-type cells, there was 
phosphorylation of PERK and eIF2 in response to the ER stress, along with enhanced 
levels of the downstream ISR target GADD34 (Figure 5B). PERK protein was not 
detected in in the PERK-/- cells, confirming the validity of our western blot analyses. 
However, it is noteworthy that there was some phosphorylation of eIF2 and presence of 
GADD34 in the PERK-deficient cells upon ER stress, although less that wild-type 
(Figure 5B). Cells with loss of primary eIF2 kinases have been suggested to engage 
alternative secondary eIF2 kinases to in part compensate (60). Consistent with this model, 
phosphorylation GCN2 was observed in both vehicle and thapsigargin treated PERK-/- 
cells but not their wild type counterparts (Figure 5B). These results suggest that 
phosphorylation of eIF2 and GADD34 expression may be attributed to compensatory 
GCN2 activation.  
 
Next, we addressed pharmacological inhibition of PERK in the wild-type MEF 
cells. The PERK+/+ MEF cells were pre-treated for 30 minutes with the inhibitors 
GSK2656157 or LY-4 followed by 4 h with thapsigargin. Cells treated with PERK 
inhibitors did not show PERK activation upon treatment with thapsigargin for 4 h (Figure 
5B). However, phosphorylation of GCN2 was again observed with the MEF cells upon 
the pharmacological inhibition of PERK activity. Furthermore, phosphorylation of eIF2 




which can be attributed to GCN2 activation. These results indicate that compounds LY-4 
and GSK2656157 are inhibitors of PERK in multiple cell types. Furthermore, upon 
genetic ablation of PERK or pharmacological inhibition of PERK, GCN2 is suggested to 
be induced as a secondary eIF2 kinase.  
 
Inhibition of PERK affects sphere formation of HCT116 cells in-vitro 
We established that PERK is activated in response to anchorage-independent 
growth conditions and it has been proposed to promote cell survival during this process. 
To test the role of PERK activity during sphere development, soft agar assays were 
performed in the presence or absence of PERK inhibitors GSK2656157 and LY-4 and 
tumorsphere growth was compared to treatment with DMSO vehicle as a control. In this 
assay, single cells are suspended in a semi-solid gel like matrix such as agar or Matrigel. 
This assay better mimics the in-vivo anchorage-independent conditions. Each treatment 
sample was seeded in triplicates (3 wells per treatment) in a 24 well plate. HCT-116 cells 
were seeded into 24-well plates at 1000 cells per well mixed with 0.7% agar containing 2 
µM of either inhibitor compound or vehicle DMSO. Normal growth media was layered 
on top of the agar matrix to ensure nutrient supply, along with same concentrations of 
compound or DMSO as in the agar layer. The assay was incubated at 37oC and after 14 
days, images of random fields of each well were captured at 10X magnification using an 
inverted compound microscope. The area of 90-95 spheres was measured using ImageJ 
software (as depicted in Figure 3 and Figure 6A) and the average area of spheres with 
PERK inhibitors was compared to DMSO control spheres. The spheres with PERK 




number of spheres per field were also counted for PERK inhibited and DMSO control 
spheres. There was a statistically significant reduction (p= 0.005 and p= 0.003) in the 
number of spheres per field in wells treated with either GSK2656157 or LY-4 as 
compared to DMSO control (Figure 6C).  These results, combined with those presented 
in figure 4, suggests that PERK activation is required for the growth of the tumorspheres. 
These results are consistent with findings by Bobrovnikova-Marjon E. et al, (45) 
suggesting that PERK is required for anchorage-independent growth of breast cancer 
cells. These results could be explained by a requirement for PERK activation in cancer 
cells growing in spheres to cope up with microenvironmental stresses such as hypoxia, 
oxidative stress, nutrient and glucose deprivation. Thus, targeting PERK activation may 






Figure 6: PERK inhibition reduces sphere formation in HCT116 cells in-vitro 
A. Representative images of soft agar assay with HCT116 cells treated with 
PERK inhibitors LY-4 (2 µM) and GSK2656157 (2 µM) compared to DMSO control. 
Representative images of one sphere per field to demonstrate difference in size of sphere. 
Area measured in pixel units. B. Quantification of sphere area and difference in area 
when treated with inhibitor as compared to DMSO control. Statistical significance was 




bar” in the box represents median, “+” represents mean, error bars represent maximum 
and minimum area of the spheres. C. Quantification of sphere count per field of soft agar 
assay treated with PERK inhibitor compared to DMSO control. Statistical significance in 
difference of spheres/field was determined by two-tailed student’s T-test at P<0.05 and 
n=30 to 40 fields. *P=0.0055; **P=0.0033; *** P=0.001 
 
PERK protein rather than its kinase activity is required for cell migration 
To address whether PERK participates in cell migration, transwell migration 
assays were performed with treated MEF cells. Migration of wild type cells was 
compared with PERK knockout cells and wild type cells treated with PERK inhibitor 
GSK2656157. The MEF cells were seeded into culture inserts for a transwell migration 
assay. The cells were seeded in media without FBS in upper chamber and the media with 
FBS was added in the lower chamber (as depicted in figure 2) to stimulate cell migration. 
For wild-type and PERK-/- cells, normal growth media was used, whereas for inhibitor 
treatment 2 µM of GSK2656157 was added to the media in both the upper and lower 
chambers. Two membranes were seeded for every treatment condition. To record the 
amount of migration, inserts with cells were removed and fixed at 1 h, 6 h, 12 h and 18 h 
timepoints to measure the number of migrated cells. The insert membrane was removed 
and stained with DAPI and images of three random fields were captured per membrane 
and average cell count per field was determined as a measure of cell migration (Figure 7 
A). All the cell counts per field were averaged and the difference in migration between 
wild type cells, those treated with inhibitor, and the PERK-deleted cells at each timepoint 




with GSK2656157 that was only significant at 12 h (Figure 7 B). However, the PERK-/- 
knockout cells showed significant reduction in migration as compared to wild type cells 
throughout 18 h time course (Figure 7 C).  These results suggest that PERK may facilitate 







Figure 7: Knockout of PERK hinders transwell migration of MEF cells 
A. Representation images of transwell cell migration of MEF cells. Pictures of a 
total of 6 fields were taken per treatment or genotype for each timepoint. Blue elliptical 
shapes of nucleus represent each cell, black apertures of the membrane pores in the 
background. B. Quantification of cell migration when treated with PERK inhibitor 
GSK2656157 compared to untreated wild type MEF cells. C. Quantification of cell 
migration of PERK-/- MEF cells compared to wild type MEF cells. Statistical significance 
in difference in cell migration at each timepoint was determined by two-tailed student’s 






From this study it was established that PERK is activated in anchorage- 
independent sphere formation of colorectal cancer cells in vitro and when PERK protein 
kinase activity is inhibited, the growth of sphere is hindered as verified by soft agar 
assays. Another potential role of PERK is in cell migration as demonstrated by ablation 
of PERK reducing transwell migration assay during a 18 h course. The role of PERK in 
migration may be more be as a scaffold protein rather than a protein kinase, as indicated 
by the difference in migration of PERK-/- cell versus the PERK inhibitor treated MEF 
cells.  
 
PERK has been shown to be activated in anchorage- independent culture 
conditions by a number of stress conditions including autophagy, hypoxia, DNA damage, 
and ROS production (48-50). In this study, the soft agar assay (Figure 6) showed that 
PERK protein kinase activity is required for sphere formation, consistent with its role as a 
UPR component. Overall, the role of PERK in anchorage-independence suggest that it is 
a good target for developing anti-cancer therapies. Lowering the chances of survival of 
cancer cells in anchorage-independent growth may reduce the rate of metastasis and 
improve the treatment of patients. However, the results noted in this study should be 
analyzed further to address which additional cellular stress conditions activate PERK. 
Following up with this study, the role of PERK in anchorage- independent growth and 
eventually in metastasis needs to be addressed using in-vivo experiments with specific 





Another finding of this study was a role for PERK in cell migration. Genetic 
deletion of PERK significantly hindered cell migration (Figure 7). By contrast, 
pharmacological inhibition of PERK protein kinase activity did not block migration of 
cells. These results suggest that PERK may serve as a scaffold protein providing for 
migration function via protein-protein interactions. The PERK-/- cells lacked part of the 
luminal domain, transmembrane domain, and part of the catalytic domain of majority of 
PERK protein synthesized. Any partial protein produced would not be stable or 
abundantly expressed. So, the parts of these domain lacking in PERK-/- cells may 
contribute to cell migration. The GSK2656157 inhibitor also shows some off-target 
effects, which might be interfering with PERK inhibition. Collectively, PERK is an 
essential protein for cell migration, although which domain of the protein is essential for 
it could not be determined. To establish the role of PERK in migration, more repetitive 
results and direct proof need to be established. To accomplish that, the migration 
experiment could be repeated with different deletions in PERK gene to compare which 
deletions affect the migration the most. Or an immunofluorescent staining of migrating 
cells can be done to determine changes in cytoskeleton during presence, absence of 
PERK or pharmacological inhibition of PERK.  
 
Recent studies also indicate a key role of UPR members, PERK and IRE1α, in 
cell migration. Consistent with the results in this study, van Vliet A. R. et al (59) showed 
that PERK knockout changes the cytoskeleton of the cell and makes the cells defective in 




almost restored to the levels observed for expression of wild-type PERK. The results 
from the studies detailed above indicates that the mere presence of PERK is required for 
normal cell migration irrespective of its kinase activity. Whereas, findings from other 
groups suggest that PERK is activated in cancer cells and facilitates cell migration 
through various downstream effectors such as MALAT1, LAMP3 and CREB3L1 via 
UPR cascade (44,54,55). 
 
In conclusion, unfolded protein response is a survival mechanism for the cells 
during stress conditions. But the cancer cells exploit this survival mechanism for their 
benefit- to survive various intrinsic and extrinsic stresses via UPR and ISR components. 
The involvement of UPR/ISR members in cancer cell survival makes them a great target 
for anti-cancer therapies. The role of PERK in cancer progression and metastasis is not 
fully explored, but the outcomes from existing studies certainly make it a target worth 
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